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Abstract: This study identified existing issues related to quantitative pharmaceutical risk 
assessment  (QPhRA,  hereafter)  for  pharmaceuticals  in  water  and  proposed  possible 
solutions by analyzing methodologies and findings of different published QPhRA studies. 
Retrospective  site-specific  QPhRA  studies  from  different  parts  of  the  world  (U.S.A., 
United Kingdom, Europe, India, etc.) were reviewed in a structured manner to understand 
different  assumptions,  outcomes  obtained  and  issues,  identified/addressed/raised  by  the 
different QPhRA studies. Till date, most of the published studies have concluded that there 
is no appreciable risk to human health during environmental exposures of pharmaceuticals; 
however,  attention is  still required to  following identified  issues: (1) Use of  measured 
versus  predicted  pharmaceutical concentration,  (2)  Identification  of  pharmaceuticals-of-
concern and compounds needing special considerations, (3) Use of source water versus 
finished  drinking  water-related  exposure  scenarios,  (4)  Selection  of  representative 
exposure routes, (5) Valuation of uncertainty factors, and (6) Risk assessment for mixture 
of  chemicals.  To  close  the  existing  data  and  methodology  gaps,  this  study  proposed 
possible  ways  to  address  and/or  incorporation  these  considerations  within  the  QPhRA 
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framework;  however,  more  research  work  is  still  required  to  address  issues,  such  as 
incorporation of short-term to long-term extrapolation and mixture effects in the QPhRA 
framework. Specifically, this study proposed a development of a new ―mixture effects-related 
uncertainty factor‖ for mixture of chemicals (i.e., mixUFcomposite), similar to an uncertainty 
factor  of  a  single  chemical,  within  the  QPhRA  framework.  In  addition  to  all  five 
traditionally used uncertainty factors, this uncertainty factor is also proposed to include 
concentration  effects  due  to  presence  of  different  range  of  concentration  levels  of 
pharmaceuticals in a mixture. However, further work is required to determine values of all 
six uncertainty factors and incorporate them to use during estimation of point-of-departure 
values within the QPhRA framework. 
Keywords: human health; pharmaceuticals; mixture toxicity; risk assessment; uncertainty 
 
1. Introduction 
In recent years, pharmaceuticals in water have received growing attention from environmental and 
health  agencies  all  over  the  world  and  have  become  one  of  the  emerging  pollutants  due  to  their 
frequent detection in the water environment [1-5]. The fact that pharmaceuticals are manufactured with 
the  intention  to  cause  biological  effects  has  raised  concerns  about  the  impacts  of  unintentional 
pharmaceutical exposure on the health of human and ecological communities. Despite the relatively 
fast growing numbers of studies on ecological/environmental risk associated with pharmaceuticals in 
water, the number of publications related to studies on human health risks remains small (Figure 1), 
however, the trend is increasing with time. Even though risk from exposure to pharmaceuticals in 
drinking  water  is  minimal  [3,6-12],  information  about  characterization  of  pharmaceuticals  is  
still lacking. 
In addition because of increasing public concern regarding potential health effects due to presence 
of pharmaceuticals in environment [13-15], it becomes important to understand and analyze different 
aspects of pharmaceutical exposures to humans, the associated health risks, and existing knowledge 
and data gaps. 
The objective of this study is to identify existing issues within the quantitative pharmaceutical risk 
assessment (QPhRA, hereafter) framework by analyzing published risk assessment methodologies and 
frameworks and propose possible suggestions and research needs. Findings of this study are expected 
to  highlight  existing  issues  within  the  QPhRA  framework  and  help  in  shaping  future  research 
directions towards filling the data and methodology gaps. Int. J. Environ. Res. Public Health 2010, 7               
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Figure  1.  Search  results  using  keywords  shown  in  legends  from  the  ―ScienceDirect‖ 
database on December 31, 2009. Note: For ―Pharmaceuticals + risk + water‖ keyword, 
total of 39,039 articles were found. For ―Personal care products+risk+water‖ keyword, 
total of 20,438 articles were found. For ―Endocrine disrupting chemicals + risk + water‖, 
total of 3,601 articles were found. 
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2. Identification of Existing Issues 
This  study  (1)  reviewed  retrospective  site-specific  quantitative  pharmaceuticals  risk  assessment 
(QPhRA) studies from different parts of the world (U.S.A., United Kingdom, Europe, India, etc.),  
(2) Analyzed information about four steps of the QPhRA methodology, and (3) Analyzed different 
identified/addressed/raised issues by different studies. The  QPhRA process helps in estimating the 
nature and probability of adverse health effects in humans who may be exposed to pharmaceuticals 
from  contaminated  environmental  media  [16].  It  primarily  involves  four  major  steps:  (1)  Hazard 
identification, (2) Exposure assessment, (3) Dose-response relationship, and (4) Risk characterization 
[3,6-12,15-18]. The reviewed retrospective site-specific QPhRA are summarized in Table 1. Following 
sections briefly discuss the stages of the QPhRA and related existing issues, needing more attention. It 
is  important  to  note  here  that  this  list  presents  a  brief  summary  of  QPhRA  studies  highlighting 
different QPhRA steps and methodologies used by these studies and it does not necessarily represent 
the complete list of all QPhRA studies published so far. 
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Table 1. Summary of previous quantitative pharmaceutical risk assessment studies for ingestion of pharmaceuticals in water. 
Reference (Country)  Hazard Identification  Exposure Assessment  Dose-response Relationship  Risk Characterization 
and Conclusions 
Christensen [7] (Denmark) 
(Academia) 
17α-ethinylestradiol (EE2), phenoxymethylpenicillin 
(Pen V), Cyclophosphamide (CP) 
Intake of drinking water, leaf crops, root crops, 
fishes, dairy products, and inhalation of air; 
 
Only one subpopulation type (adults: 70 kg  
body weight) 
For EE2: Higher intake from 
fish than other medium; For 
PenV and CP: Higher intakes 
from drinking water than other 
medium 
 
For PenV-at least 10 
international units of penicillin 
(5.9 μg penicillin) is required to 
trigger a mode of action. 
 
For CP-toxic endpoint is 
genotoxicity (i.e., a genotoxic 
carcinogen) 
 
No consideration for mixture 
effect 
 
Negligible human risks;  
 
For the case of  
PenV-considerations are 
required for sensitive 
population which may 
react with few molecules; 
More risk assessment 
studies for other 
veterinary drugs 
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Table 1. Cont. 
Reference (Country)  Hazard Identification  Exposure Assessment  Dose-response Relationship  Risk Characterization 
and Conclusions 
Schulman et al. [11] 
(Europe) (Academia) 
Acetylsalicylic acid, clofibrate, cyclophosphamide, 
indomethacin 
 
Ingestion of water and consumption of fish 
 
Water ingestion rate: 2 L/d (adults); Fish ingestion 
rate: 0.0178 kg/d general population and sports 
anglers, 0.039 kg/d subsistence fishers;  
 
Body weights: 70 kg (adults) and 30 kg(children) 
 
  No health risks 
Webb et al. [12] (Europe) 
(Academia and Industry) 
Acetyl salicylic acid, clofibric acid, ibuprofen, 
gemfibrozil, fenoprofen, ketoprofen, diclofenac, 
fenofibric acid, bezafibrate, indometacine, salicylic 
acid, atenolol, sotalol, salbutamol, terbutalin, 
fenoterol, nadolol, metropolol, celiprolol, carazolol, 
clenbuterol, phenazone, ifosfamide, 
cyclophosphamide, carbamazepine, pentoxifylline, 
clofibrate, phenazone, dimethlaminophenazon, 
ifosfamide, cyclophosphamide, carbamazepine, 
pentoxifylline, diazepam, fenofibrate, etofibrate, 
clarithromycin, dehydrato-erythromycin, 
roxithromycin, sulfamethazine, sulfamethoxazole, 
trimethoprim, chloramphenicol, chloroteracycline, 
doxycycline, tetracycline, cloxacillin, dicloxacillin, 
methicillin, nafcillin, oxacillin, benzylpenicillin, 
phenoxymethylpenicillin, iopamidol, iopromide, 
ioxithalamic acid, iothalamic acid, diatrizoate,  
17α-Ethinylestradiol 
 
Ingestion of water  
 
Water ingestion rate: 2 L/d (adults);  
 
 
 
Comparisons of daily intake 
values (or dose equivalent  
for exposures for 70 years)  
with minimum daily  
therapeutic dose; 
 
No consideration for  
mixture effect 
Low possibility of  
health risks Int. J. Environ. Res. Public Health 2010, 7               
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Table 1. Cont. 
Reference (Country)  Hazard Identification  Exposure Assessment  Dose-response Relationship  Risk Characterization 
and Conclusions 
Schwab et al. [3] (U.S.A.) 
(Industry) 
Acetaminophen, ablution, cimetidine, ciprofloxacin, 
codeine, dehydronifedipine, digoxigenin, digoxin, 
diltiazem, doxycycline, enalaprilat,  
erithromycin-H2O, fluoxetine, gemfibrozil, 
ibuprofen, lincomycin, metformin, norfloxacin, 
oxytetracycline, paroxetine metabolite, ranitidine, 
sulfamethoxazole, sulfathiazole, tetracycline, 
trimethoprim, warfarin 
Ingestion of surface water and consumption of fish 
 
Water ingestion rate: 2 L/d (adults) and 1 L/d 
(children); Fish ingestion rate: 0.0175 kg/d (adults) 
and 0.0065 kg/d (children);  
 
Both subpopulation types with  
body weights = 70 kg (adults) and  
14 kg (children); also inclusion of elderly and  
infirm where pharmacologic effect is undesirable 
 
Non-volatile active pharmaceutical ingredients => 
inhalation exposure is neglected; Similarly, dermal 
exposure pathways is assumed to contribute smaller 
risk compared to incidental ingestion risks 
 
Use of both measured and 
predicted environmental 
concentrations and comparison 
of these values with calculated 
predicted-no-effect 
concentration (PNEC) values 
(separately for consumption of 
drinking water, fish, and for 
simultaneous consumption of 
both drinking water and fish) 
 
No consideration for  
mixture effect 
 
 
No appreciable risks  
to humans 
 
Due to smaller values of 
bioconcentration factors, 
fish consumption is 
unlikely to be major 
exposure pathway 
Watts et al. [19] (U.K.) 
(Industry and Academia) 
396 pharmaceuticals and 11 illicit drugs  Ingestion of surface water 
 
Water ingestion rate: 1 L/d (adults)  
(no considerations for sensitive subpopulation) 
 
Calculation of surface water pharmaceutical 
concentration using the European Medicines 
Agency (EMA) models 
 
Comparison of minimum 
therapeutic dose (MTD) with 
estimated exposure dose 
 
Quantitative consideration for 
mixture effect 
 
No human health risks 
(margin-of-safety 
observed >1,000 for 
most of the drugs 
except for some drugs 
where ratios were 
observed to be below 
100, when combination 
of 19 NSADI were 
used with MTD value. 
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Table 1. Cont. 
Reference (Country)  Hazard Identification  Exposure Assessment  Dose-response Relationship  Risk Characterization 
and Conclusions 
Bercu et al. [6] (U.S.A.) 
(Industry) 
Atomoxetine,duloxetine, olanzapine 
(neuropharmaceutical compounds) 
 
 
Ingestion of surface water and consumption of fish 
 
Water ingestion rate: 2 L/d (adults) and 1 L/d 
(children) 
Fish ingestion rate: 0.0175 kg/d (adults) and  
0.013 kg/d (children) 
 
Body weights: 70 kg (adults) and 30 kg(children) 
 
Calculation of surface water pharmaceutical 
concentration using the USFDA (1998) and 
PhFATE surface water models 
Determination of lowest 
relevant effect dose using 
preclinical and clinical studies 
and its use for calculation of 
ADI; Use of human study for 
estimation of point-of-departure 
(POD) if effect is same from 
both animal and human studies 
and use of animal study with 
uncertainty factors for 
estimation of POD. 
Use of default uncertainty 
factors in the case of 
insufficient data for 
extrapolation purposes and 
where applicable, use of clinical 
trial data (i.e., chemical-
specific-adjustment factors) 
accounting human variability  
Calculation of predicted no-
effect concentration (PNEC) in 
water, assuming that ADI could 
be delivered through drinking 
water and by eating fish 
 
No consideration for  
mixture effect 
No appreciable  
health risks Int. J. Environ. Res. Public Health 2010, 7               
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Table 1. Cont. 
Reference (Country)  Hazard Identification  Exposure Assessment  Dose-response Relationship  Risk Characterization 
and Conclusions 
Snyder [18] (U.S.A.) 
(Government) 
Atenolol, atorvastatin, carbamazepine, diazepam, 
diclofenac, enalapril, fluoxetin, gemfibrozil, 
meprobamate, naproxen, phenytoin, risperidone, 
simvastatin, sulfamethoxazole, triclosan, 
trimethoprim 
 
    No health risks 
Johnson et al. [20] (UK) 
(Academia) 
Cytotoxic chemotherapy drugs (5-fluorouracil, 
cyclophosphamide, epirubicin/doxorubicin) 
 
Ingestion of water 
 
Water ingestion rate: 1.5 L/d (adults) 
Body weight: 70 kg (adults) 
Prediction of concentration for 
5-fluorouracil and comparison 
with 10 ng/L trigger cytotoxic 
concentration value for humans; 
and comparison with PNEC 
value for aquatic fauna 
 
No consideration for  
mixture effect 
 
No appreciable  
health risks 
Rowney et al. [17] (UK) 
(Academia) 
Three cytotoxic drug groups: alkylating agents 
(oxaliplatin, temozolomide, cisplatin, carboplatin, 
cyclophosphamide), antimetabolites (gemcitabine, 
fludarabine, fluorouracil-a metabolite to the prodrug 
capecitabine), and anthracycline antibiotics 
(epirubicin, doxorubicin).  
Calculation of predicted environmental 
concentration using information, such as drug use, 
excretion rate and removal in sewage treatment 
plant and dissipation (assumed to be negligible)  
and dilution considerations in stream water 
 
Ingestion of raw stream water (using predicted  
drug concentrations for mean and 90th percentile 
flow conditions);  
Water ingestion rate: 2 L/d (adults) 
 
Comparison of PEC estimates 
with threshold-of-toxicological-
concern (TTC) and  
no-significant-risk-levels 
(NSRLs). 
 
No consideration for  
mixture effects 
No health risks Int. J. Environ. Res. Public Health 2010, 7               
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Table 1. Cont. 
Reference (Country)  Hazard Identification  Exposure Assessment  Dose-response Relationship  Risk Characterization 
and Conclusions 
Cunningham et al. [8] 
(U.S.A.) (Industry) 
44 active pharmaceutical ingredients marketed by 
GlaxoSmithKline 
Ingestion of water and consumption of fish 
 
Water ingestion rate: 1.5 L/d (adults) and 1 L/d 
(children); Fish ingestion rate = 0.0065 kg/d 
Both subpopulation types with  
body weights = 70 kg (adults) and 14 kg (children) 
Use of both measured and 
predicted environmental 
concentrations and their 
comparisons with PNEC levels; 
Use of threshold of 
toxicological concern 
No consideration for  
mixture effect 
No appreciable health 
risks 
Crider et al. [21] (U.S.A.) 
(Academia) 
Penicillins, erythromycins, cephalosporins, 
sulfonamides, quinolones, tetracyclines, 
aminoglycosides, and nitrofurantoins 
Exposure : Reported maternal use of these 
antibiotics (1 month before the pregnancy  
through the end of the first trimester); 
 
A retrospective case-control study  
Calculated Odds ratio and 
measured association of 
antibiotic use and selected  
birth defects 
No consideration for  
mixture effect 
Penicillins erythromycins, 
cephalosporins:  
No association with  
birth defects. 
Sulfonamides, 
nitrofurantoins: 
Association with several 
birth defects 
Schriks et al. [22] 
(Netherlands) (Academia) 
50 chemicals in surface, groundwater,  
and drinking water 
Water ingestion rate: 2 L/d (adults) 
 
Adult subpopulation with 70 kg body weight  
 
Compared environmental 
concentration with threshold  
of toxicological concern 
For chemicals in surface water 
and groundwater, a benchmark 
quotient of 0.2 is used as 
chemicals are removed in 
drinking water treatment  
plants also. 
No consideration for  
mixture effect 
No appreciable health 
concern Int. J. Environ. Res. Public Health 2010, 7               
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Table 1. Cont. 
Reference (Country)  Hazard Identification  Exposure Assessment  Dose-response Relationship  Risk Characterization 
and Conclusions 
Cunningham et al. [9] 
(U.S.A.) (Industry) 
Carbamazepine and its metabolites (carbamazepine 
diol and carbamazepine N-glucuronide) 
Ingestion of water and consumption of fish 
 
Water ingestion rate: 1.5 L/d (adults) and 1 L/d 
(children); Fish ingestion rate = 0.0065 kg/d 
 
Both subpopulation types with  
body weights = 70 kg (adults) and 14 kg (children) 
(consideration for sensitive subpopulation) 
 
Use of both measured and 
predicted environmental 
concentrations and their 
comparisons with PNEC levels; 
Use of threshold of 
toxicological concern 
 
No consideration for  
mixture effect 
 
No appreciable health 
risks 
Kumar and Xagoraraki [10] 
(U.S.A.)/ (Academia)  
Carbamazepine, phenytoin, meprobamate in U.S. 
surface water and finished drinking water 
Ingestion of water and consumption of fish during 
recreational activity and direct consumption of 
finished drinking water 
 
Water ingestion rate: 0.1 L/d for surface water and  
2 L/d for finished drinking water; Fish ingestion  
rate = 0.020 kg/d 
 
Both subpopulation types with  
body weights = 70 kg (adults in 18–75 years age 
group) and children of 1–10 years age group with 
body weight (kg) = 8 + 2 ×  Age) 
Use of sub-population specific 
toxic endpoints; Use of 
calculated therapeutic- and 
toxicity- based acceptable daily 
intake values 
 
Consideration for mixture effect 
qualitatively (No reported 
interactions of meprobamate 
with phenytoin and 
carbamazepine at therapeutic 
concentration levels; Reported 
interaction of carbamazepine 
with phenytoin (decrease in 
pharmaceutical concentration 
due to presence of other 
pharmaceutical compound) 
No appreciable health 
concern Int. J. Environ. Res. Public Health 2010, 7               
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2.1. Hazard Identification 
2.1.1. Measured versus predicted pharmaceutical concentration 
Generally, both detected and modeled pharmaceutical concentrations are used in estimating risk for 
humans due to pharmaceuticals in water. The different pharmaceuticals studied can be seen in Table 1. 
With  the  advancement  of  detection  techniques  for  pharmaceuticals  in  the  environment,  there  are 
extensive published data on the occurrence of pharmaceuticals in water [4,18], some of which have 
been  used  in  risk  assessment  studies.  For  example,  the  results  of  the  national  reconnaissance  for 
pharmaceuticals and other contaminants in U.S. streams conducted by the U.S. Geological Survey 
during 1999 and  2000  [23] was used  by Schwab  et  al. [3] to  conduct the risk  assessment. Also,  
Benotti  et  al.  [1]  analyzed  20  pharmaceuticals  in  source  water,  finished  drinking  water,  and 
distribution system water from 19 U.S. water utilities between 2006 and 2007. These occurrence data 
are  useful  for conducting QPhRA,  especially for the assessment of risks associated with  drinking  
water consumption.  
Modeled pharmaceuticals concentrations in water have also been used in different QPhRA studies. 
For  example,  two  commonly  used  models  are:  (1)  Pharmaceutical  Assessment  and  Transport 
Evaluation  (PhATE)  [24]  and  (2)  Geography-referenced  Regional  Exposure  Assessment  Tool  for 
European Rivers [GREAT-ER,17,25]. The PhATE model is used to obtain predicted environmental 
concentrations (PECs) of active pharmaceutical ingredients (APIs) that results from patient’s use of 
medicines in 11 watersheds selected to be representative of most hydrologic regions of the U.S. [24]. It 
estimates values of PECs at drinking water locations and at stream segments based on flow summary 
statistics. The GREAT-ER model estimates concentrations of pharmaceuticals in stream segments of 
ten  watersheds  in  Belgium,  France,  Germany,  the  U.K.  and  Netherlands  by  using  Monte  Carlo 
simulation  to  generate  distributions  of  concentrations  in  segments  which  reflect  the  variability  of 
various model parameters [8,17].  
In  general,  modeled  pharmaceutical  concentrations  are  used  in  the  case  of  no  availability  of 
appropriate concentration data and are useful for those substances which might be present at very low 
levels in environment. However, very few studies have validated these models before using for risk 
assessment  purposes,  suggesting  the  need  for  extensive  model  validation  with  field  observed 
pharmaceutical  concentration  data.  Further,  proper  considerations  are  also  important  for 
pharmaceuticals with low environmental concentrations due to problems with analytical detection methods. 
2.1.2. Pharmaceuticals-of-concern 
The review of pharmaceuticals studied during different QPhRA studies, summarized in Table 1, 
indicates  that  studies  have  conducted  risk  assessment  on  a  diverse  range  of  pharmaceuticals  in 
environmental  waters  depending  on  multiple  criteria,  such  as  occurrence,  analytical  capability, 
chemical properties, public perception, and possible health effects [3,6-12,15-18]. The selection of 
important pharmaceuticals in water depending on multiple criteria and subsequent risk assessment is a 
complex  task.  Although,  different  prioritization  approaches  are  available  for  identifying Int. J. Environ. Res. Public Health 2010, 7               
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pharmaceuticals-of-concern in both stream water and finished drinking water [10,22], they have not 
yet been integrated with the QPhRA framework.  
The integration of pharmaceutical prioritization frameworks with the QPhRA frameworks has the 
potential of providing a  holistic tool  to different  stakeholders  for conducting  pharmaceuticals risk 
assessment on a priority-basis. With regards to types of pharmaceuticals, a constant update of the 
pharmaceuticals  list  is  required  to  include  all  newly  detected  pharmaceuticals,  such  as  different 
metabolites  and  transformed  products  from  parent  organic  compounds  [26-28],  depending  on 
advancement of analytical methods.  
It is worth noting here that  the list of emerging organic compounds  detected in environmental 
waters is increasing everyday due to improved detection of metabolites and transformed products from 
parent compounds [28], and this, frequent update of prioritized list is required to reflect occurrence of 
newly detected compounds in environmental waters. The developed lists should be region-specific 
reflecting concentration profiles of pharmaceuticals on a water body-level. Findings of the Larsson et al. 
[14] study illustrated the need for taking this kind of prioritization approach, where they reported very 
high levels of pharmaceuticals in wastewater effluent in Pantanchery (INDIA), with the most abundant 
pharmaceutical ciprofloxacin reaching up to 31,000 μg/L concentration level. Further, Schwab et al. [3] 
also proposed to consider regional effect during prediction of pharmaceuticals consumption and thus 
excreted  pharmaceutical  concentration  levels  in  domestic  wastewater.  These  reported  findings 
illustrate the need for conducting water body-level QPhRA and avoid the practice of generalization the 
QPhRA risk estimates for different exposure scenarios. 
2.2. Exposure Assessment 
2.2.1. Exposure routes 
Most of the previous QPhRA studies have used scenario evaluation-based approach for estimating 
risk using different assumptions for developing exposure [3,6-12,17-21] (Table 1). This approach is 
one of the three U.S. EPA recommended approaches for exposure assessment [29] and it involves 
consideration of exposures through oral ingestion route, which generally happens during consumption 
of finished drinking water and/or fish (Table 1). This approach is consistent with the criteria used for 
estimating  predicted-no-effect-concentration  (PNEC)  for  pharmaceuticals  in  water  [30];  however, 
other indirect exposure scenarios are also possible. For example, exposure to pharmaceuticals could 
also occur in following scenarios: (1) Indirect ingestion of food crops and/or vegetables irrigated with 
reclaimed wastewater or grown on sewage-sludge-amended soil [2], (2) Inhalation of pharmaceuticals 
during application of reclaimed wastewater for irrigation purposes, and (3) Dermal exposure. Most of 
the previous QPhRA studies have generally ignored these exposure scenarios, assuming a relatively 
smaller risk estimate from these scenarios compared to direct exposure scenario [3,10], which could be 
valid  for  pharmaceuticals  with  low  vapor  pressure  but  not  for  different  class  of  pharmaceuticals. 
Review of most of the QPhRA studies indicates that comprehensive risk assessment studies including 
different exposure routes are required for different classes of pharmaceuticals. 
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2.2.2. Exposure-related parameters 
Exposure-related  parameters  (such  as  human  ingestion  rate  and  exposure  duration)  have  been 
generally obtained using scenario-specific information during the hazard identification step and also 
using information given in the U.S. EPA Exposure Factors Handbook [31]. In addition, assumptions 
are  also  made  in  the  absence  of  exposure-related  data  for  pharmaceutical  concentration,  exposure 
frequency,  and  exposure  duration.  For  example,  studies  have  used  surface  water  pharmaceutical 
concentration for estimating risk due to pharmaceuticals in finished drinking water, assuming that the 
drinking water treatment plant  (DWTP) does  not  remove  any  pharmaceuticals from surface water 
[3,8,11,12,32]. Although, this approach is a conservative way of checking if there is any risk due to 
surface water, it does not represent the effect of water treatment plant on fate of pharmaceuticals and 
possible  production  of  any  other  metabolites,  which  might  be  more  dangerous  than  the  parent 
pharmaceutical  compound  [12,26].  For  example,  a  brief  review  of  removal  of  different 
pharmaceuticals from full-scale DWTPs (Table 2) shows that some of the pharmaceutical compounds 
are removed completely from water whereas some of other pharmaceutical compounds are persistent 
in water in a conventional DWTP. Also, most of the pharmaceutical compounds investigated were 
found to be removed more than 90% from water in advanced DWTP. These findings indicate that the 
effect of removal effectiveness of different plant types should be included in QPhRA. For the case of 
low pharmaceutical-based exposure risks from stream water, related pharmaceutical-based exposure 
risks  from  finished  drinking  water  would  also  be  smaller  due  to  effect  of  DWTP  in  removing 
pharmaceuticals  from  water.  Considering  this  aspect,  use  of  a  source-specific  pharmaceutical 
concentration is recommended for risk estimation purposes. 
2.3. Dose-Response Relationship 
2.3.1. Uncertainty factors 
This  step  involves  estimation  of  (1)  response  values  (i.e.,  chronic  daily  intake  (CDI)  of 
pharmaceutical compounds) using exposed pharmaceutical dose and (2) benchmark values to compare 
calculated exposed pharmaceutical dose. For non-cancer effects, the exposed dose is usually compared 
with a health-based limit (HBL) (such as reference dose (RfD) or acceptable daily intake (ADI)); for 
carcinogenic  effects,  the  dose  is  usually  compared  with  a  risk-specific  dose  (RSD)  (i.e.,  dose 
associated with a target risk, for example 10
−6, 10
−5, etc.) and estimations of these benchmark values 
generally  involve  utilization  of  results  from  previous  toxicity  assessment  studies  [32]  and 
characterization of safety/uncertainty factors (UFs). 
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Table 2. Removals of emerging organic chemicals in drinking water treatment plans: (a) Conventional treatment: Combination of filtration 
(sand), clarification, GAC adsorption, and chlorination unit processes and (b) Advanced treatment: Combination of conventional treatment 
unit processes with ozonation, ultra-violet irradiation, membrane filtration unit processes) [1,4]. 
  Less than 90% removal  More than 90% removal 
Conventional treatment 
Name of 
chemicals 
4-nonylphenol; 7-Acetyl-1,1,3,4,4,6-Hexamethyl-1,2,3,4-
tetrahydronaphthalene (AHTN); bisphenol A; codeine; 
dehydronifedipine; Diethoxyoctylphenol (OP2EO); 
methylbenzyldene camphor; sulfathiazole; tri(2-butoxyethyl) 
phosphate; triclosan; triethylcitrate;  
Tris (2-chloroethyl)phosphate (TCEP)  
 
17β-estradiol; acetaminophen; atorvastatin; benzophenone-3; 
carbamazepine; carbaryl; clofibric acid; diazepam; diazinon; diclofenac; 
erythromycin; estrone; fluoxetine; gemfibrozil; HHCB; lincomycin; 
metolachlor; naproxen;progesterone; sulfamethoxazole; trimethoprim  
 
Advanced treatment 
Name of 
chemicals 
4-nonylphenol; triclosan; TCEP  Atenolol; atrazine; bezafibrate; carbamazepine; clofibric acid; cotinine; 
diclofenac; estrone; gemfibrozil; ibuprofen; linuron; meprobamate; 
metolachlor; N,N-diethyltoluamide (DEET); naproxen; phenytoin; 
progesterone; sulfamethoxazole 
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Generally, uncertainty factors have been classified into five categories: (1) Intraspecies variability 
(i.e., human to human) (UF1), (2) Interspecies variability (i.e., extrapolation from animal to human) 
(UF2),  (3)  Extrapolation  from  subchronic  to  chronic  exposure  (UF3),  (4)  Extrapolation  from  
low-observable-adverse-effect-level  (LOAEL)  estimate  to  no-observable-adverse-effect-level 
(NOAEL) estimate (UF4), (5) Database quality and extrapolation (UF5), and a modifying factor based 
on professional assessment (MF). A review of different QPhRA studies indicated that the degree to 
which UFs were investigated and utilized varied significantly. Unlike NOEL estimates determined 
from toxicity studies, selection of UF values involve more subjective judgment [3] and presents a state 
of  difficulty.  Some  studies  have  used  default  values  of  different  UFs,  depending  on  types  of 
uncertainties they represent. For example, Schulman et al. [11] considered only UF1 and UF4 types of 
uncertainties and used a default value of 30 for the combination of these two factors. Schwab et al. [3], 
Cunningham  et  al.  [8],  and  Kumar  and  Xagoraraki  [10]  discussed  all  five  types  of  UFs  and 
incorporated them into the development of ADIs. 
Recently,  some  researchers  have  advocated  the  derivation  and  use  of  non-default  values  for  
UFs [3,6]. For example, Bercu et al. [6] essentially used UF1, UF2 and UF4 types of uncertainty factors 
in  their  risk  assessment  studies  and  used  non-default  values  for  some  of  these  UFs.  The  use  of  
non-default values of UFs for deriving estimates of ADIs appears to be a more representative approach 
as it does not include any extrapolation-based assumption and it determines values of UFs depending 
on uncertainty type and other considerations. Depending on availability of pharmaceutical-based data, 
non-default  values  representing  toxicodynamics  and  toxicokinetics  of  different  pharmaceuticals  
(i.e., chemical-specific adjustment factors) should be used [6,26].  
In  addition,  the  uncertainty  of  long-term/chronic  effects  associated  with  exposure  to 
pharmaceuticals in water has also been mentioned in most of the previous QPhRA studies (Table 1). 
Considerations of interactions of exposure duration and environmental pharmaceuticals concentrations 
become important due to the fact that some pharmaceuticals are designed to achieve acute effects and 
some  pharmaceuticals  are  designed  to  achieve  chronic  effects.  Although,  the  current  QPhRA 
methodology  uses  uncertainty  factor  (UF3)  to  account  for  sub-chronic  to  chronic  exposure 
extrapolation  long-term effects  might occur  at relatively lower  concentrations  than those tested in 
toxicity experiments and might follow different toxicodynamic mechanisms than those extrapolated 
from short-term studies [20]. Thus, more long-term toxicity studies or experimental-simulation based 
hybrid approach are required to predict long-term toxicity effects.  
2.3.2. Endpoints 
A chemical may elicit more than one toxic effect (i.e., endpoint), even in one test animal, resulting 
in  different  NOEL  values  corresponding  to  different  effects  [32].  Generally,  the  identification  of 
toxicological properties of a given pharmaceutical during QPhRA may include analyses of all possible 
health endpoints. However, due to constraints of time and resources, an in-depth analysis is rarely 
carried out for each health endpoint. For certain pharmaceuticals, endpoints might be defined from 
different types of experiments to further calculate values of ADIs. Uncertainties exist with the choice 
of endpoint and thus with the estimation of ADI values [3]. For example, Webb et al. [12] used Int. J. Environ. Res. Public Health 2010, 7               
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toxicologically-based  ADI,  microbiologically-based  ADI,  pharmacologically-based  ADI,  and  also 
therapeutic dosage as estimate of ADI similarly to other studies [6,8,11]. 
A direct consequence of identification of different endpoints is the generation of different ADIs for 
chemicals, which can be a source of considerable confusion when the ADIs are used exclusively in risk 
management decision making [32]. The use of different approximations for calculating ADI estimates 
poses  an  uncertainty  in  risk  estimates,  needing  proper  consideration.  Theoretically,  the  critical 
endpoint used in the dose-response assessment should be the effect exhibiting the lowest NOEL [32]. 
However, in the previous practice of QPhRA, significant differences often exist between the ADIs of 
the same pharmaceutical calculated by different studies (Table 3). For example, for antibiotics such as 
doxycycline, tetracycline, and oxytetracycline, Webb et al. [12] used 3µ g/kg/d whereas Schwab et al. [3] 
used 30 µ g/kg/d as estimates of ADI values for each of these three antibiotics (Table 3). The primary 
reason of discrepancy of ADI estimates between these two studies was that Webb et al. [12] used 
therapeutic doses for estimating ADI values whereas Schwab et al. [3] used ADI value, developed on 
the  basis  of  antimicrobial  resistance  of  human  intestinal  microflora  using  the  WHO  guidelines. 
Different estimates of ADI values for other pharmaceutical compounds such as cyclophosphamide, 
acetylsalicylic acid are also shown in Table 3. These observations illustrate the importance of proper 
selection of endpoint for a given receptor. 
At present, since most of the previous QPhRA studies have reported no appreciable human health 
risks  associated  with  pharmaceuticals  in  water,  the  diversified  choices  of  health  endpoints  do  not 
essentially  make  a  significant  difference  in  risk  characterization.  However,  if  new  circumstances 
emerge, different choices of endpoint might lead to different results of risk characterization, and even 
different decisions by risk management groups. From this point of view, it might be necessary to invest 
efforts  to  standardize  or  give  authoritative  reference  on  the  general  choice  of  endpoints  of 
pharmaceuticals in water regarding QPhRA studies, or even provide reference values of ADIs. 
During determination of endpoints, proper consideration of receptor’s susceptibility to the particular 
pharmaceutical  is  also  required.  For  pharmaceuticals,  while  the  therapeutic  effect  is  considered 
beneficial for patient population, no benefit is presumed to be received by the individuals incidentally 
exposed to pharmaceuticals  via ingesting  drinking  water or  consuming  fish, and  hence it is often 
treated as an adverse effect in many QPhRA studies. For some pharmaceuticals that are developed for 
just one gender or age class, the therapeutic dose for the target population may not be the appropriate 
point-of-departure  (POD)  for  calculating  values  of  ADI  for  the  non-targeted  population,  and 
consequently they may need individual evaluation [3,8]. Although the attention is generally given to 
the most sensitive adverse effect and sometimes, the lowest therapeutic dose has been used as the most 
―sensitive‖ POD for estimating values of ADI [3,8,10,12], this approach does not represent the effect 
of a pharmaceutical on a specific subpopulation type. For example, Kumar and Xagoraraki [10] used 
two types of ADI values (i.e., toxicity- and therapeutic-based ADI values) for both adults and children 
subpopulations for estimating risks due to exposures of carbamazepine, meprobamate, and phenytoin 
from  stream  water  or  finished  drinking  water.  For  proper  characterization  of  risk  estimates,  this 
approach  appears  to  be  preferable  as  it  provides  a  better  understanding  about  characterization  of  
risk estimates. 
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Table  3.  Summary  of  previous  studies  using  different  acceptable  daily  intake  (ADI)  values  for  the  same  pharmaceutical  compound 
(Information about endpoints considered during estimation of ADI values are presented in parentheses). 
Pharmaceutical name  Webb et al. [12] 
(assumed body weight = 60 kg) 
Schwab et al. [3]  Schulman et al. [11] 
(assumed body weight 
= 60 kg) 
Christensen [7] 
Acetylsalicylic acid  8.3 µ g/kg/d 
(30 mg/day therapeutic dose as 
anticoagulation therapy) 
Not applicable  16.67 µ g/kg/d   Not applicable 
Cyclophosphamide  16.67 µ g/kg/d 
(1 mg/d based on immunobullous skin 
disorders) 
Not applicable  0.017 µ g/kg/d 
(1 µ g /d based on  
no-significant-risk-level) 
0.01 µ g/d 
(for rat) 
Doxycycline  3 µ g/kg/d 
(100 mg/day therapeutic dose based on 
bacterial infection) 
30 µ g/kg/d 
(value established from WHO representing antimicrobial 
sensitivity of human intestinal microflora) 
Not applicable  Not applicable 
Tetracycline  3 µ g/kg/d 
(1,000 mg/day therapeutic dose based on 
bacterial infection) 
30 µ g/kg/d 
(value established from WHO representing antimicrobial 
sensitivity of human intestinal microflora) 
Not applicable  Not applicable 
Oxytetracycline  3 µ g/kg/d 
(1,000 mg/day therapeutic dose based on 
bacterial infection) 
30 µ g/kg/d 
(value established from WHO representing antimicrobial 
sensitivity of human intestinal microflora) 
Not applicable  Not applicable 
17α-ethinylestradiol  0.167 µ g/kg/d 
(0.010 mg/d therapeutic dose based on 
menopausal symptoms) 
Not applicable  Not applicable  6 µ g/d 
(prepubescent 
boys) 
Phenoxymethyl-penicillin  16666 µ g /kg/d 
(1,000 mg/day therapeutic dose based on 
bacterial infection) 
Not applicable  Not applicable  5.9 µ g/d 
Clofibrate  8333 µ g /kg/d 
(500 mg/d therapeutic dose based on 
hyperlipoproteinaemia) 
Not applicable  278 µ g/kg/d   Not applicable Int. J. Environ. Res. Public Health 2010, 7               
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In addition, special considerations are also required for some classes of pharmaceuticals, such as 
antibiotics  (i.e.,  with  non-human  target  effects;  for  example:  trimethoprim,  tetracycline, 
oxytetracycline,  doxycycline),  chemicals  with  therapeutic  dose  above  a  toxic  dose  (i.e.,  cytotoxic 
effect; for example: cyclophosphamide), chemicals which have high allergenic responses (for example: 
benzyl penicillin, phenoxymethyl-penicillin), or chemicals with high bioaccumulation potentials (for 
example: 17α-estradiol) ([3,7,12,17],Table 3). For example, cancer risk exists at any concentration 
levels  of  cyclophosphamide  thus  the  therapeutic-based  benchmark  cannot  be  used  for  this 
pharmaceutical  compound  [17,33].  Antibiotics  present  a  cause  of  concern  due  to  their  reported 
occurrence  in  environmental  media  and  due  to  their  potential  for  inducing  antibiotic  resistance. 
Although sufficient margin-of-safety has been observed during exposures of these pharmaceuticals 
from the aquatic environment [8,17], proper consideration and risk estimation are required for the case 
of occurrence of very high levels of antibiotics in wastewater effluents as reported recently by the 
Larsson et al. [14] and Phillips et al. [28] studies (concentration: >1,000 µ g/L). Proper considerations 
are required during estimation of POD for pharmaceuticals with regards to their pharmacological or 
allergenic effects once their therapeutic effects subside. Overall, values of PODs should be estimated 
based on interaction of pharmaceuticals with endpoint-under consideration for a given subpopulation. 
Further, PODs should not be used interchangeably for different subpopulations, unless assumptions 
and conditions are documented adequately.  
2.3.3. Sensitive subpopulation 
Proper considerations of gender or age class are also required during estimation of representative 
ADI for QPhRA for different sensitive subpopulations (i.e., pregnant women, elderly, and children). 
For some pharmaceuticals that are developed for just one gender or age class, the therapeutic dose for 
the target population may not be the appropriate point-of-departure (POD) for calculating estimates of 
ADI for non-targeted population. Although an uncertainty factor of 10 is usually used to account for 
the variability among humans, its strength in protecting the special subpopulation remains difficult to 
verify for different pharmaceuticals, found in drinking water sources, thus these subpopulations need 
individual evaluations [3,6,9,10,11]. 
2.3.4. Mixture effects 
As  occurrence  of  multiple  pharmaceuticals  in  water  at  low  concentrations  have  been  
reported  [1,4,13,23,33],  consideration  of  their  interactions  in  QPhRA  becomes  important  as  it 
constitutes  an  important  uncertainty  [3,8,11].  Due  to  lack  of  understanding  about  (1)  actual 
composition  of  pharmaceutical  mixtures  and  (2)  toxicity  of  pharmaceuticals  at  low  concentration 
levels in mixture of other pharmaceuticals, it becomes difficult to predict bodily responses to mixture 
of pharmaceuticals. A review of QPhRA studies presented in Table 1 indicates that so far, most of the 
QPhRA studies have considered risk assessment due to individual pharmaceuticals and none of them 
have considered effect of mixtures of different pharmaceuticals. Recently Kumar and Xagoraraki [10] 
used  information  about  carbamazepine,  meprobamate,  and  phenytoin  provided  by  the  RxList  to 
understand their interaction with each other using a pair of two active pharmaceutical ingredients 
(APIs) (Table 1) and qualitatively discussed the potential effect of simultaneous presence of different Int. J. Environ. Res. Public Health 2010, 7               
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APIs. Although this approach appears to serve the purpose of understanding the interactive effect of 
APIs, it does not help in getting quantitative risk estimates.  
To circumvent the issue of QPhRA of mixture of pharmaceuticals in water, studies have generally 
discussed different assumptions following the U.S.EPA [33] guideline for health risk assessment of 
chemical mixtures. Further, due to the present use of consideration of different UFs for estimation of 
HBLs  and  its  subjectivity,  the  current  QPhRA  methodology  overestimates  risk  estimates  and  is 
expected to compensate the effect of simplified assumption of consideration of no mixture effect on 
risk estimates.  
Due  to  the  potential  additive,  antagonistic,  or  synergistic  nature  of  pharmaceuticals,  any 
comprehensive  risk  assessment  method  addressing  the  issue  of  mixture  effects  is  expected  to  be 
complicated  [11,18]. Generally, the  additive effect due  to  different pharmaceuticals  is  expected if 
pharmaceuticals act through the same mechanism  [34]. It is worth noting here that Cleuvers  [33] 
reported that even  at concentrations  at which  the single  substance showed no or  only  very slight 
effects, toxicity of the mixture was considerable [33]. Further these effects could be concentration-
dependent as Pomati et al. [35] observed during their toxicity study using 13 drugs. A summary of 
these toxicity studies using mixtures of chemicals is presented in Table 4. Although most of these 
studies have assessed toxicity using aquatic indicator species or non-specific tests [21,33,34], findings 
of these studies provide perspectives about affects due to presence of different pharmaceuticals at 
different levels. For example, findings of Cleuvers [33] or Pomati et al. [35] are useful in conducting 
ecological risk assessment for aquatic species due to mixture of these pharmaceuticals within the range 
of concentration levels studied. Recently, Watts et al. [19] considered mixture toxicity quantitatively in 
QPhRA and estimated exposure ratio (i.e., ratio of minimum therapeutic dose (MTD) to environmental 
dose) for total of 19 non-steroidal-anti-inflammatory-drugs (NSAIDs) by combining their exposure 
dose values and using lowest value of MTD (i.e.,7.5 mg for meloxicam), illustrating the approach for 
addressing mixture effects in QPhRA quantitatively.  
In  general,  more  toxicological  work  is  required  to  study  interactive  effects  of  different 
pharmaceuticals present in water on different end points. To use the observed mixture effects data 
(Table  4)  for  conducting  QPhRA  for  humans,  we  propose  to  use  a  composite  uncertainty  factor 
representing  effect  of  mixture  of  pharmaceuticals  on  endpoint  of  a  particular  pharmaceutical,  i.e., 
―mixture  effects-related  uncertainty  factor‖  ( composite mixUF , hereafter).  The  composite mixUF parameter 
consists  of  all  different  types  of  uncertainty  factors  for  a  given  mixture  of  ph armaceuticals 
(i.e., i mixUF ), similar to five uncertainty factors used for a single pharmaceutical (Section 2.3.1) and 
an  additional  uncertainty  factor  representing  consideration  for  concentration  levels  of  different 
pharmaceuticals in mixture (i.e., 6 mixUF ). Using Equation (1), values of  composite mixUF for a given 
pharmaceutical in a mixture of pharmaceuticals could be calculated and used further to calculate POD 
using relationships previously used for a single pharmaceutical compound [3]. 



6
1 k
k composite mixUF mixUF   (1) 
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Table 4. Literature-reported mixture effects of pharmaceuticals. 
Reference  Component chemicals of mixture  Testing approach  Observed mixture effects 
Silva et al. [34]  Eight chemicals of environmental relevance:  
2’,3’,4’,5’-tetrachloro-4-biphenylol, 2’,5’-dichloro-4biphenylol, 
4’-chloro-4-biphenylol, genistein, 2,4-dihydroxybenzophenone, 
benzyl-4-hydroxyparabene, bisphenol A,  
resorcinol monobenzoate 
 
Recombinant yeast 
estrogen screen (YES) 
There were substantial mixture effects even 
though each chemical was present at levels 
well below its NOEC and EC01. 
Cleuvers [33]  Diclofenac, ibuprofen, naproxen, acetylsalicylic acid  Acute Daphnia and  
algal tests 
Toxicity of the mixture was considerable, 
even at concentrations at which the  
single substances showed no or only very  
slight effects. 
 
Pomati et al. [35]  A mixture of 13 different drugs at environmentally relevant 
concentrations: atenolol, bezafibrate, carbamazepine, 
ciprofloxacin, cyclophosphamide, furosemide, 
hydrochlorothiazide, furosemide, hydrochlorothiazide, 
ibuprofen, lincomycin, ofloxacin, ranitidine, salbutamol, 
sulfamethoxazole 
 
in vitro cytotoxicity in 
Escherichia coli, human 
embryonic HEK293, and 
estrogen-responsive 
OVCAR3 tumor cells 
(1) Drugs could interact and behave as 
chemosensitizers, with joint effects 
representing a statistically significant 
element of mixture toxicity. 
(2) Effects and interactions were 
concentration dependent. Int. J. Environ. Res. Public Health 2010, 7               
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Currently, due to lack of detailed knowledge about different  i mixUF  (i = 1 to 6), further research 
efforts should be focused on getting values for these uncertainty factors for handling issues of mixture 
effects  of  pharmaceuticals  in  QPhRA.  Further  exploration  of  Quantitative  Structure -Activity 
Relationship  (QSAR)  modeling  techniques  and  other  toxicogenomics  and  probabilistic   
approaches [26] could possibly help in understanding and determining values of uncertainty factors for 
mixture of pharmaceuticals. 
3. Conclusions 
This study reviewed different QPhRA studies to identify existing issues and proposed possible 
suggestions to address these issues, as summarized in Table 5. In general, for low concentrations of 
APIs, none of the QPhRA studies has identified any human health risks via exposure to drinking water, 
but uncertainties related to the QPhRA still exist and warrant consideration. The existing findings do 
not rule out the possibility of any human health. As the present risk values are estimated based on very 
limited knowledge about chronic effects and mixture effects of pharmaceuticals, this study proposes a 
development of a new ―mixture effects-related uncertainty factor‖ for mixture of pharmaceuticals, 
similar to an uncertainty factor used for a single chemical within the QPhRA framework. In addition to 
all five traditionally used uncertainty factors, this factor is also proposed to include concentration 
effects due to presence of different concentration levels of pharmaceuticals in a mixture. However, 
further work is required to determine these factors and incorporate them within the QPhRA framework. 
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Table 5. Summary of identified issues related to QPhRA and possible suggestions. 
Issue   Issue description  Research needs/Suggestions 
Measured versus  
predicted pharmaceutical concentration 
Very few predictive models for pharmaceutical concentrations 
have been validated [8,9,24,25]; It is difficult to model  
low-detected pharmaceuticals. 
Validate models using measured concentrations ; Conduct uncertainty  
analysis of risk estimates to address issue of low detection. 
 
Pharmaceuticals-of-concern  The list of both parent compounds and metabolites is consistently 
increasing [12,25,28] and it becomes difficult to conduct QPhRA 
for all detected compounds. 
Update pharmaceuticals list and integrate prioritization approach with the 
QPhRA framework [36]. 
Pharmaceuticals needing special 
attention 
Therapeutic dose-based POD estimates might not represent 
effects of anti-neoplastics, antibiotics, bioaccumulative, allergens, 
and metabolites on different subpopulations [7,8,9,3,12]. 
Consider final effects of these pharmaceuticals on different receptors during 
estimation of POD and conduct group-specific QPhRA for these 
pharmaceuticals. 
Source water versus finished drinking 
water 
Use of source water pharmaceutical concentration for risk 
estimation as a conservative approach for exposures to 
pharmaceutical from finished drinking water [6,8,25,12]. 
Conduct water source-specific QPhRA;  
Use source water pharmaceutical concentration as finished drinking water 
pharmaceutical if data on pharmaceutical concentration in finished drinking 
water is missing. 
Exposure route   Assumed dominance of oral ingestion route compared to other 
indirect ingestion- or inhalation-related exposure routes [2,3,12]. 
Conduct pharmaceutical class-specific comprehensive QPhRA studies using 
all exposure routes for a given receptor. 
Values uncertainty factors (UFs)  Uncertainty exists due to different choices of values of UFs 
[3,6,12].  
Use chemical-specific adjustment factors (CSAFs) [6,26]; Use default UF 
values only if CSAFs are not available. 
Conduct long-term toxicity studies or combination of experiment-simulation 
based studies to predict long-term toxicity using short-term toxicity data to 
address the issue of uncertainty related to short-term/long-term extrapolation. 
Sensitive subpopulation  For some pharmaceuticals that are developed for just one gender 
or age class, the therapeutic dose for the target population may 
not be the appropriate point-of-departure (POD) for calculating 
estimates of ADI for non-targeted population (i.e., pregnant 
women, elderly, children) 
Use subpopulation-specific POD values [3,6,8,9,11,12]; Use uncertainty factor 
equal to 10 only in the absence of subpopulation-related endpoints 
information.  
Mixture effects   Co-occurrence of different pharmaceuticals in water may affect 
risk estimates. 
Discuss all assumptions involved during QPhRA for mixture of 
pharmaceuticals [33]. 
Conduct more toxicity studies to develop mixture effects-related  
uncertainty factors. Int. J. Environ. Res. Public Health 2010, 7               
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